We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
+33.69%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$66.1M
AUM Growth
+$21.2M
(+47%)
Cap. Flow
+$13.7M
Cap. Flow
% of AUM
20.71%
Top 10 Holdings %
Top 10 Hldgs %
79%
Holding
27
New
5
Increased
8
Reduced
4
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTC Therapeutics
PTCT
|
+$6.98M |
| 2 |
ACOR
Acorda Therapeutics
ACOR
|
+$5.3M |
| 3 |
XNPT
XENOPORT, INC.
XNPT
|
+$5.2M |
| 4 |
UnitedHealth
UNH
|
+$4.17M |
| 5 |
Quest Diagnostics
DGX
|
+$2.21M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DaVita
DVA
|
+$4.07M |
| 2 |
Stryker
SYK
|
+$2.61M |
| 3 |
MiMedx Group
MDXG
|
+$2.22M |
| 4 |
ENDP
Endo International plc
ENDP
|
+$1.84M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$1.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
PTC Therapeutics
PTCT
$6.37B
| $7.68M | 11.62% |
+237,100
| New | +$6.98M |
|
|
XNPT
2
DELISTED
XENOPORT, INC.
XNPT
| $7.11M | 10.76% |
1,295,778
+927,383
| +252% | +$5.2M |
|
|
3
Quest Diagnostics
DGX
$25.1B
| $6.65M | 10.05% |
93,445
+32,925
| +54% | +$2.21M |
|
|
ACOR
4
DELISTED
Acorda Therapeutics
ACOR
| $6.22M | 9.41% |
+1,213
| New | +$5.3M |
|
5
Centene
CNC
$31.3B
| $5.67M | 8.57% |
172,278
+70,710
| +70% | +$2.09M |
|
6
Teva Pharmaceuticals
TEVA
$35.9B
| $4.94M | 7.47% |
75,286
+27,201
| +57% | +$1.68M |
|
|
7
UnitedHealth
UNH
$382B
| $4.2M | 6.35% |
+35,686
| New | +$4.17M |
|
8
Edwards Lifesciences
EW
$47.6B
| $3.73M | 5.64% |
141,690
-23,754
| -14% | -$617K |
|
|
NVRO
9
DELISTED
NEVRO CORP.
NVRO
| $3.71M | 5.61% |
54,927
-6,733
| -11% | -$361K |
|
10
Alkermes
ALKS
$8.82B
| $2.33M | 3.52% |
+29,350
| New | +$2.06M |
|
11
Neurocrine Biosciences
NBIX
$17.7B
| $2.31M | 3.5% |
40,888
-8,612
| -17% | -$438K |
|
|
IPXL
12
DELISTED
Impax Laboratories, Inc.
IPXL
| $2.2M | 3.33% |
51,430
+13,151
| +34% | +$525K |
|
|
AERI
13
DELISTED
Aerie Pharmaceuticals
AERI
| $2.09M | 3.16% |
85,895
+61
| +0.1% | +$1.42K |
|
14
Pacific Biosciences
PACB
$422M
| $1.91M | 2.89% |
+145,306
| New | +$1.3M |
|
|
FOLD
15
DELISTED
Amicus Therapeutics
FOLD
| $1.89M | 2.86% |
195,206
-37,751
| -16% | -$340K |
|
|
ANAC
16
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $1.76M | 2.66% |
15,591
+6,242
| +67% | +$688K |
|
|
SGYP
17
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $1.72M | 2.6% |
303,157
+100,002
| +49% | +$610K |
|
|
18
Bristol-Myers Squibb
BMY
$127B
| – | – |
-29,900
| Closed | -$1.77M |
|
|
19
DaVita
DVA
$15.1B
| – | – |
-56,290
| Closed | -$4.07M |
|
|
20
MiMedx Group
MDXG
$626M
| – | – |
-229,839
| Closed | -$2.22M |
|
21
Penumbra
PEN
$12.5B
| – | – |
-9,980
| Closed | -$400K |
|
|
22
Stryker
SYK
$127B
| – | – |
-27,781
| Closed | -$2.61M |
|
23
Vanda Pharmaceuticals
VNDA
$312M
| – | – |
-118,707
| Closed | -$1.34M |
|
|
CLVS
24
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – |
-16,458
| Closed | -$1.51M |
|
|
ENDP
25
DELISTED
Endo International plc
ENDP
| – | – |
-26,600
| Closed | -$1.84M |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q4 2015 Portfolio in Review
As of Q4 2015, Asymmetry Capital Management held 27 positions worth $66.1M, up 47% from $44.9M the previous quarter. Its ten largest holdings account for 79% of the portfolio.
Asymmetry Capital Management deployed $13.7M of net new capital in Q4 2015, opening 5 new positions and adding to 8 existing holdings. Its largest new stake was PTC Therapeutics: 237,100 shares worth $7.68M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier.
On the sell side, the largest reduction was Edwards Lifesciences, an estimated $617K trimmed.
- Asymmetry Capital Management's largest Q4 2015 buy was PTC Therapeutics: 237,100 shares worth $7.68M.
- Asymmetry Capital Management added most to XENOPORT, INC. in Q4 2015, an estimated $5.2M increase.
- Asymmetry Capital Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $617K.
- Asymmetry Capital Management fully exited DaVita in Q4 2015, selling an estimated $4.07M.
- Asymmetry Capital Management's ten largest holdings make up 79% of its $66.1M portfolio in Q4 2015.
- Asymmetry Capital Management opened 5 new positions and closed 10 in Q4 2015.
- Asymmetry Capital Management's portfolio value rose 47% quarter-over-quarter to $66.1M.
Based on Asymmetry Capital Management's 13F filing for Q4 2015, filed 3 Feb 2016.